Primary immunodeficiencies and lymphoma: a systematic review of literature

References

• Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96–128.
   PubMed Web of Science ®Google Scholar
• Seleman M, Hoyos-Bachiloglu R, Geha RS, et al. Uses of next-generation sequencing technologies for the diagnosis of primary immunodeficiencies. Front Immunol. 2017;8:847.
   PubMed Web of Science ®Google Scholar
• Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018;141(3):1028–1035.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Mathur A, Kamat D, et al. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res. 52(19 Suppl):5465s–5467s.
   PubMed Web of Science ®Google Scholar
• Salavoura K, Kolialexi A, Tsangaris G, et al. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28:1263–1269.
   PubMed Web of Science ®Google Scholar
• Leechawengwongs E, Shearer WT. Lymphoma complicating primary immunodeficiency syndromes. Curr Opin Hematol. 2012;19(4):305–312.
   PubMed Web of Science ®Google Scholar
• Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286.
   PubMed Web of Science ®Google Scholar
• Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–1657.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547–1554.
   PubMed Web of Science ®Google Scholar
• Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116.e11–126.e11.
   Web of Science ®Google Scholar
• Suarez F. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034–3044.
   PubMed Web of Science ®Google Scholar
• Shapiro RS. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol. 2011;86(1):48–55.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes. CA: Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French lymphopath network. J Clin Oncol. 2017;35(18):2008–2017.
   PubMed Web of Science ®Google Scholar
• Fischer A, Provot J, Jais J-P, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immun. 2017;140(5):1388–1393.e8.
   PubMed Web of Science ®Google Scholar
• Latour S, Winter S. Inherited immunodeficiencies with high predisposition to Epstein–Barr virus-driven lymphoproliferative diseases. Front Immunol. 2018;9:1103.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Palendira U, Edwards E. Human immunity against EBV—lessons from the clinic. J Exp Med. 2017;214(2):269–283.
   PubMed Web of Science ®Google Scholar
• Brandau O, Schuster V, Weiss M, et al. Epstein–Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the Sh2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet. 1999;8(13):2407–2413.
   PubMed Web of Science ®Google Scholar
• Morra M, Howie D, Grande MS, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol. 2001;19(1):657–682.
   PubMedGoogle Scholar
• Morra M, Simarro-Grande M, Martin M, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001;276(39):36809–36816.
   PubMed Web of Science ®Google Scholar
• Sumazaki R, Kanegane H, Osaki M, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood. 2001;98(4):1268–1270.
   PubMed Web of Science ®Google Scholar
• Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53–62.
   PubMed Web of Science ®Google Scholar
• Schmid JP, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117(5):1522–1529.
   PubMed Web of Science ®Google Scholar
• Marsh RA, Bleesing JJ, Chandrakasan S, et al. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transpl. 2014;20(10):1641–1645.
   PubMed Web of Science ®Google Scholar
• Somekh I, Marquardt B, Liu Y, et al. Novel mutations in RASGRP1 are associated with immunodeficiency, immune dysregulation, and EBV-induced lymphoma. J Clin Immunol. 2018;38(6):699–710.
   PubMed Web of Science ®Google Scholar
• Winter S, Martin E, Boutboul D, et al. Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein–Barr virus susceptibility. EMBO Mol Med. 2018;10(2):188–199.
   PubMed Web of Science ®Google Scholar
• Salzer E, Daschkey S, Choo S, et al. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica. 2013;98(3):473–478.
   PubMed Web of Science ®Google Scholar
• Alkhairy OK, Perez-Becker R, Driessen GJ, et al. Novel mutations in TNFRSF7/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol. 2015;136(3):703–712.e10.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Bienemann K, Boztug K, et al. Interleukin-2-inducible T-cell kinase (ITK) deficiency—clinical and molecular aspects. J Clin Immunol. 2014;34(8):892–899.
   PubMed Web of Science ®Google Scholar
• Li F-Y, Chaigne-Delalande B, Su H, et al. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. 2014;123(14):2148–2152.
   PubMed Web of Science ®Google Scholar
• Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated PI3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2016;139(2):597.e4–606.e4.
   Web of Science ®Google Scholar
• Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210–218.e9.
   PubMed Web of Science ®Google Scholar
• Egg D, Schwab C, Gabrysch A, et al. Increased risk for malignancies in 131 affected CTLA4 mutation carriers. Front Immunol. 2018;9:2012.
   PubMed Web of Science ®Google Scholar
• Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98(1):194–200.
   PubMed Web of Science ®Google Scholar
• Price S, Shaw PA, Seitz A, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–1999.
   PubMed Web of Science ®Google Scholar
• Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118(18):4798–4807.
   PubMed Web of Science ®Google Scholar
• Guffroy A, Mourot-Cottet R, Gérard L, et al. Neutropenia in patients with common variable immunodeficiency: a rare event associated with severe outcome. J Clin Immunol. 2017;37(7):715–726.
   PubMed Web of Science ®Google Scholar
• Boileau J, Mouillot G, Gérard L, et al. Autoimmunity in common variable immunodeficiency: Correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun. 2011;36(1):25–32.
   PubMed Web of Science ®Google Scholar
• Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85.
   PubMed Web of Science ®Google Scholar
• Odnoletkova I, Kindle G, Quinti I, et al. The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet J Rare Dis. 2018;13:201.
   PubMed Web of Science ®Google Scholar
• Taylor A. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer. Br J Cancer. 1992;66(1):5–9.
   PubMed Web of Science ®Google Scholar
• Kutluk MT, Yalcin B, Büyükpamukçu M. Ataxia telangiectasia and Hodgkin disease. Med Pediatr Oncol. 2000;35(5):509.
   PubMedGoogle Scholar
• Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French National Registry of Primary Immune Deficiencies. J Clin Oncol. 2015;33(2):202–208.
   PubMed Web of Science ®Google Scholar
• Verhoeven D, Stoppelenburg AJ, Meyer-Wentrup F, et al. Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Clin Immunol. 2018;190:22–31.
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903–907.
   PubMed Web of Science ®Google Scholar
• Taylor JG, Liapis K, Gribben JG. The role of the tumor microenvironment in HIV-associated lymphomas. Biomarkers Med. 2015;9(5):473–482.
   PubMed Web of Science ®Google Scholar
• Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602.e1-11–610.e1-11.
   Web of Science ®Google Scholar
• Fox TA, Chakraverty R, Burns S, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. 2018;131(8):917–931.
   PubMed Web of Science ®Google Scholar